Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 12, 2007, Pages 1443-1449

  Chu, E C ^a   Chai, J ^a   Ahluwalia, A ^a   Tarnawski, A S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 5; MESALAZINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LABELING INDEX; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANNEXIN A5; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MESALAMINE; PROTO-ONCOGENE PROTEINS C-MYC; TREATMENT OUTCOME;

EID: 34249781974     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03336.x     Document Type: Article

References (30)

1. Narisawa T, Fukaura Y. Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats. Dis Colon Rectum 2003 46 : 900 3.
2. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003 24 : 443 51.
3. Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000 32 : 245 54.
4. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era Aliment Pharmacol Ther 1999 13 : 1397 402.
5. Pinczowksi D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994 107 : 117 20.
6. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996 8 : 1179 83.
7. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000 14 : 145 53.
8. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001 44 : 77 85.
9. Berstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003 98 : 2784 8.
10. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005 100 : 1345 53.
11. Allgayer H. Review article: Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003 18 (Suppl. 2 10 4.
12. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-kappaB RelA/p65 phosphorylation by mesalazine is accompanied by decreased transcriptional activity. J Biol Chem 1999 274 : 26448 53.
13. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000 95 : 3452 7.
14. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000 119 : 1209 18.
15. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005 201 : 1205 15.
16. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 1985 8 : 1969 76.
17. Ciclitira PJ, Macartney JC, Evan G. Expression of c-myc in non-malignant and pre-malignant gastrointestinal disorders. J Pathol 1987 151 : 293 6.
18. Pavelic ZP, Pavelic L, Kuvelkar R, Gapany SR. High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res 1992 12 : 171 5.
19. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005 16 : 2485 501.
20. Tao L, Kramer PM, Wang W, et al. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis 2002 23 : 1447 54.
21. Kishimoto Y, Yashima K, Morisawa T, Shiota G, Kawasaki H, Hasegawa J. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. J Gastroenterol 2002 37 : 186 93.
22. Imaseki H, Hayashi H, Taira M, et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer 1989 64 : 704 9.
23. Erisman MD, Scott JK, Watt RA, Astrin SM. The c-myc protein is constitutively expressed at elevated levels in colorectal carcinoma cell lines. Oncogene 1988 2 : 367 78.
24. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998 281 : 1509 12.
25. Yamakawa-Karakida N, Sugita K, Inukai T, et al. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ 2002 9 : 513 26.
26. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002 50 : 658 64.
27. Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990 4 : 523 33.
28. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990 31 : 1271 6.
29. Jacobsen BA, Abildgaard K, Rasmussen HH, et al. Availability of mesalazine '5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol 1991 26 : 374 8.
30. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1998 42 : 761 3.